InterVenn

InterVenn is a life science company focused on glycoproteomics, the study of glycosylated proteins that play a crucial role in protein function. The company's pioneering AI-powered platform aims to decode the glycoproteome, which contains vital information about human biology, thereby enhancing patient outcomes. InterVenn's technology facilitates the identification, quantification, and classification of glycoproteomic signals found in blood and tissue, enabling early detection and diagnosis of cancers, particularly ovarian cancer. This platform not only supports clinical applications such as disease screening and diagnostics but also offers valuable insights for pharmaceutical partners involved in research and development. Founded by notable scientists, including Nobel Laureate Dr. Carolyn Bertozzi, InterVenn is positioned to advance personalized, predictive, and preventative healthcare solutions.